Ceramide Delivery via Organic Solvent and BSA Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering bioactive lipids, such as ceramide, face challenges due to their hydrophobic nature, limited cell permeability, and rapid metabolism, making systemic delivery to cells ineffective for therapeutic applications, particularly in cancer and cardiovascular diseases.
Innovation Solution
The development of nanoscale assembly systems like pegylated liposomes, resorbable nanoparticles, and polymeric materials that enhance lipid solubility, cell permeability, and circulation half-life, allowing for targeted delivery of bioactive compounds and gene therapy agents, including ceramide, to specific tissues or tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If short-chain, cell-permeable ceramide analogues are used, then cell permeability is improved, but they still precipitate as fine lipid micelle suspensions due to hydrophobicity
Solution Approach 1:
The patent uses organic solvent systems (dodecane/ethanol) as intermediaries to solubilize hydrophobic ceramide analogues. The solvent system acts as a bridge between the hydrophobic lipid and the aqueous cellular environment, preventing precipitation while maintaining cell permeability. The solvent forms micelles that encapsulate the ceramide, allowing it to remain in solution until delivery to the target cell.
Solution Approach 2:
The patent modifies the physical-chemical parameters of ceramide delivery by changing the solvent system from traditional aqueous vehicles to organic solvent systems (dodecane/ethanol). This parameter change alters the solubility characteristics, allowing hydrophobic ceramide analogues to remain dissolved rather than precipitating as micelles, while still enabling cellular uptake.
2Adaptability or versatility
If ceramide is delivered systemically, then therapeutic coverage is improved, but circulating and intracellular ceramidases promote conversion into less pro-apoptotic metabolites
Solution Approach 1:
The patent employs protein adjuvants, specifically bovine serum albumin (BSA), to pre-protect ceramide from enzymatic degradation. BSA binds to ceramide in the circulation, shielding it from ceramidases before it reaches target cells. This preliminary protective action maintains ceramide integrity during systemic transit, ensuring therapeutic efficacy is preserved.
Solution Approach 2:
The patent uses protein adjuvants as intermediary carriers that temporarily bind to ceramide during systemic circulation. This intermediary relationship protects the ceramide from enzymatic conversion by ceramidases, allowing it to reach target tissues intact while maintaining its pro-apoptotic activity.
3Productivity
If organic solvent systems are used to augment ceramide delivery, then delivery efficiency is improved, but variability in particle size and access to cellular membranes increases
Solution Approach 1:
The patent optimizes the organic solvent system composition (dodecane/ethanol ratios) and ceramide concentration to control micelle formation. By adjusting these parameters, the patent reduces variability in particle size while maintaining the solubilization and delivery efficiency benefits of organic solvents. The optimized formulation ensures more uniform micelle dimensions for consistent cellular access.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These systems improve the delivery and efficacy of bioactive lipids by stabilizing ceramide within liposomes, ensuring optimal intercalation into cell membranes, evading immune clearance, and achieving sustained release and targeted accumulation in tumor tissues, leading to enhanced apoptosis and growth inhibition in cancer cells.
Implementation Method 1
PEG-C8 formulated liposomes ensures optimal intercalation and localization of the free ceramide into caveolin-rich lipid rafts, a pre-requisite for membrane internalization
Implementation Method 2
approaches to deliver bioactive lipids into living cells are not generally available. The delivery of bioactive sphingolipids and phospholipid metabolites, analogues, mimetics or derivatives and their intercalation into cells is impeded by their physical-chemical properties that render these lipids hydrophobic and cell impermeable
Data Source
AI summary
A system and method for optimizing the systemic delivery of growth-arresting lipid-derived bioactive drugs or gene therapy agents to an animal or human in need of such agents utilizing nanoscale assembly systems, such as liposomes, resorbable and non-aggregating nanoparticle dispersions, metal or semiconductor nanoparticles, or polymeric materials such as dendrimers or hydrogels, each of which exhibit improved lipid solubility, cell permeability, an increased circulation half life and pharmacokinetic profile with improved tumor or vascular targeting.